معرفی
Boris Kantor serves as an Adjunct Professor in the Department of Neurobiology at Duke University and is a Faculty Network Member of the Duke Institute for Brain Sciences. He directs the Kantor Lab, which operates the Duke University Viral Vector Core—a critical resource providing viral vector production services for gene transfer research to investigators across neuroscience, stem cell biology, metabolism, aging, and cancer biology both within Duke and globally.
His educational trajectory includes a Postdoctoral Fellowship at the University of North Carolina, Chapel Hill (2005-2009), a Ph.D. from The Hebrew University of Jerusalem (2005), an M.Sc. from the same institution (1998), and an earlier Ph.D. from Grodno State Medical University (1995).
Dr. Kantor's research pioneers viral vector-based gene therapy for neurodegenerative disorders, specializing in adeno-associated virus (AAV) and lentiviral delivery systems for epigenome editing and CRISPR/Cas9 applications. His work targets allele-specific regulation of disease genes like APOEε4 in Alzheimer's and SNCA in Parkinson's, with emphasis on precision medicine approaches. The Viral Vector Core under his leadership enables cutting-edge translational studies through optimized vector design and production.
Analysis of his recent publications (2021-2025) reveals a dominant focus on AAV-delivered epigenome-editing platforms for neurodegenerative conditions, particularly addressing challenges in vector safety, tissue specificity, and therapeutic efficacy for CNS disorders. His work consistently bridges molecular innovation with clinical applicability in neurodegeneration.
Dr. Kantor has secured substantial research funding including:
- Untangling genetic architecture of late-onset Alzheimer's using single-cell multi-omics (2022-2026)
- Novel epigenome-editing therapy for Parkinson's targeting SNCA (2022-2025)
- AAV production for Kallyope (2023-2025)
- Gene therapy for ATP1A3-related disease (2023-2025)
- APOE-targeted precision therapy for Alzheimer's (2022-2023)
The Kantor Lab functions as an integrated research and service hub, advancing vector technologies while supporting over a dozen active grants spanning neurodegenerative disease modeling, therapeutic development, and clinical translation through its viral vector production pipeline.
